APA (7th ed.) Citation

Morita‐Fujita, M., Arai, Y., Kondo, T., Harada, K., Uchida, N., Toya, T., . . . Kako, S. (2022). Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI. Hematological oncology, 40(5), 1041-1055. https://doi.org/10.1002/hon.3046

Chicago Style (17th ed.) Citation

Morita‐Fujita, Mari, et al. "Adult Patients with Ph+ ALL Benefit from Conditioning Regimen of Medium‐dose VP16 Plus CY/TBI." Hematological Oncology 40, no. 5 (2022): 1041-1055. https://doi.org/10.1002/hon.3046.

MLA (9th ed.) Citation

Morita‐Fujita, Mari, et al. "Adult Patients with Ph+ ALL Benefit from Conditioning Regimen of Medium‐dose VP16 Plus CY/TBI." Hematological Oncology, vol. 40, no. 5, 2022, pp. 1041-1055, https://doi.org/10.1002/hon.3046.